FCN-159 is a novel, proprietary and highly potent inhibitor of mitogen-activated protein kinase kinase enzymes (MEK).  It is being developed by Fochon as a monotherapy and in combination to treat solid tumors.

MEK is a key member in the RAS/RAF/MEK/ERK pathway, which regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis. Dysregulation of this pathway frequently occurs in many types of cancer, in particular through mutations in BRAF, KRAS and NRAS.

FCN-159 exhibited enhanced in vitro and in vivo potency compared to approved MEK inhibitor trametinib (GSK1120212), with excellent physical, pharmakinetic and safety properties suitable for combination therapies.

Mechanism of Action